Legend Biotech Corp Cash Flow Conversion Efficiency
Legend Biotech Corp cash flow conversion efficiency. Based on the latest financial reports, Legend Biotech Corp (LEGN) has a cash flow conversion efficiency ratio of -0.017x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.90 Million) by net assets ($1.23 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see LEGN market cap for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Legend Biotech Corp (2017–2025)
Cash flow conversion efficiency of Legend Biotech Corp from 2017 to 2025. This chart illustrates how Legend Biotech Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Legend Biotech Corp stock quote for real-time trading data and today's change.
Legend Biotech Corp Cash Flow Conversion Ratio Explained
Legend Biotech Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Legend Biotech Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Legend Biotech Corp ranked by their cash flow conversion efficiency. Review LEGN free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen MTC Co Ltd
SHE:002429
|
0.033x |
|
Ningbo Joyson Electronic Corp
SHG:600699
|
0.074x |
|
AP Memory Technology Corp
TW:6531
|
0.051x |
|
Turkcell Iletisim Hizmetleri AS
NYSE:TKC
|
0.003x |
|
Faw Car Co Ltd
SHE:000800
|
-0.031x |
|
Xinfengming Group Co Ltd
SHG:603225
|
0.089x |
|
Shanghai Wanye Enterprises Co Ltd
SHG:600641
|
-0.075x |
|
Vontobel Holding
SW:VONN
|
0.544x |
Annual Cash Flow Conversion Efficiency for Legend Biotech Corp (2017–2025)
The table below shows the annual cash flow conversion efficiency of Legend Biotech Corp from 2017 to 2025. Also see LEGN asset base for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.00 Billion | $-100.47 Million | -0.100x | +27.57% |
| 2024-12-31 | $1.04 Billion | $-144.03 Million | -0.138x | +55.96% |
| 2023-12-31 | $1.25 Billion | $-393.28 Million | -0.314x | -16.22% |
| 2022-12-31 | $744.31 Million | $-201.28 Million | -0.270x | -4.37% |
| 2021-12-31 | $765.94 Million | $-198.47 Million | -0.259x | +30.31% |
| 2020-12-31 | $599.82 Million | $-223.00 Million | -0.372x | -154.99% |
| 2019-12-31 | $-122.87 Million | $-83.06 Million | 0.676x | -98.10% |
| 2018-12-31 | $8.65 Million | $307.68 Million | 35.574x | +18315.35% |
| 2017-12-31 | $12.17 Million | $-2.38 Million | -0.195x | -- |
About Legend Biotech Corp
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of mult… Read more